GU Cancers 2023 | Identifying optimal candidates for active surveillance in prostate cancer

Anthony Victor D’Amico, MD, PhD, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA, discusses the role of molecular biomarkers and imaging in identifying optimal candidates for active surveillance among patients with prostate cancer. Prof. D’Amico also talks on how lifestyle factors can impact the immune system. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.